A new survey has found that even though the cost of medicinal cannabis has significantly decreased over the past year the pricing is still too high for many Australians. Patients are required to cover all of the cost of their treatment as no cannabis medications are subsidised by the Pharmaceutical Benefits Scheme (PBS). As a result many of them are looking for cheaper alternatives on the black market. Read the article here.
ANTG has listed two new THC-dominant medicinal cannabis strains on the Australian Register of Therapeutic Goods (ARTG).
We are focused on research and development, partnering with leading scientists and medical institutions to develop cannabinoid medicines that offer safe and effective therapeutic benefits.LEARN ABOUT ANTG HERE >